From raj at cellabs.com.au  Mon Nov  7 04:52:20 2016
From: raj at cellabs.com.au (Dr G-Halli Rajasekariah)
Date: Mon, 7 Nov 2016 17:52:20 +1100
Subject: [Leish-l] Leish-l Digest, Vol 101, Issue 2
In-Reply-To: <mailman.135.1478297940.2658.leish-l@lineu.icb.usp.br>
References: <mailman.135.1478297940.2658.leish-l@lineu.icb.usp.br>
Message-ID: <029c01d238c3$7cea1720$76be4560$@cellabs.com.au>

Hello Everybody, 
We have a very good antibody testing  for dogs against Leishmaniasis and
both specific ELISA as well as specific  IFAT  format are also available. 

If you have any problem please do not hesitate to contact me.

Dr G-Halli Rajasekariah
Cellabs Pty Ltd
Unit 7 No 27 Dale St
Brookvale NSW 2100
sales at cellabs.com.au 
Tel 612 99050133
Email raj at cellabs.com.au


-----Original Message-----
From: leish-l-bounces at lineu.icb.usp.br
[mailto:leish-l-bounces at lineu.icb.usp.br] On Behalf Of
leish-l-request at lineu.icb.usp.br
Sent: Saturday, 5 November 2016 9:19 AM
To: leish-l at lineu.icb.usp.br
Subject: Leish-l Digest, Vol 101, Issue 2

Send Leish-l mailing list submissions to
	leish-l at lineu.icb.usp.br

To subscribe or unsubscribe via the World Wide Web, visit
	http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
or, via email, send a message with subject or body 'help' to
	leish-l-request at lineu.icb.usp.br

You can reach the person managing the list at
	leish-l-owner at lineu.icb.usp.br

When replying, please edit your Subject line so it is more specific than
"Re: Contents of Leish-l digest..."


Today's Topics:

   1. RES:  Looking for sources of Leishmania positive serum
      (TECSA - Luiz Ristow)


----------------------------------------------------------------------

Message: 1
Date: Fri, 21 Oct 2016 18:37:35 -0200
From: "TECSA - Luiz Ristow" <ristow at tecsa.com.br>
Subject: [Leish-l] RES:  Looking for sources of Leishmania positive
	serum
To: "'Rita Melo'" <RMelo at tspot.com>,	<leish-l at lineu.icb.usp.br>
Message-ID: <08a001d22bda$f7001b90$e50052b0$@tecsa.com.br>
Content-Type: text/plain; charset="us-ascii"

Dear Rita 

 

We have lots of animal (canine) serum positive for Leishmaniosis 

Sorry we don't have human but if you know companies envolved in research ,
production of animal tests please send to me 

I need in special serological /detection of Ag of Cats and Dogs diseases 

Thank you 

 

 

 

 

 

Atenciosamente,

 

 

 

 

 

 



 

 

De: leish-l-bounces at lineu.icb.usp.br
[mailto:leish-l-bounces at lineu.icb.usp.br] Em nome de Rita Melo Enviada em:
segunda-feira, 10 de outubro de 2016 16:46
Para: leish-l at lineu.icb.usp.br
Assunto: [Leish-l] Looking for sources of Leishmania positive serum

 

Hi,

 

We are a lab located in Massachusetts, in the US and we are looking for
sources of Leishmania positive human serum/blood. 

We would really appreciate if you could help us with this in any way, for
example by directing us to the right person or laboratory.

 

Thanks,

Rita

 

Rita Melo-Nazareno, Pharm.D., Ph.D. 

R&D Scientist II

Development

Oxford Immunotec 

5846 Distribution Drive

Memphis TN 38141

United States 

Mobile: 901 462 42 98

Email: rmelo at tspot.com <mailto:rmelo at tspot.com> 

www.oxfordimmunotec.com <http://www.oxfordimmunotec.com/> 

www.tspot.com <http://www.tspot.com/> 

 

 

  _____  


This email is confidential and is not intended to be read by anyone other
than the named recipient. If you have received this email in error, please
notify us immediately by reply email and then delete this message from your
system. Please do not copy this email or use it for any purpose or disclose
its contents to any other person (since this could be a breach of
confidence) and any hard copy should be destroyed immediately. Thank you for
your co-operation.
Oxford Immunotec Limited
94C Innovation Drive
Milton Park, Abingdon, Oxfordshire OX14 4RZ Registered in England No.4516079


--
This email was sent by icb.usp.br   --  

-------------- next part --------------
An HTML attachment was scrubbed...
URL:
<http://lineu.icb.usp.br/pipermail/leish-l/attachments/20161021/4f160e86/att
achment.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: image/png
Size: 46683 bytes
Desc: not available
URL:
<http://lineu.icb.usp.br/pipermail/leish-l/attachments/20161021/4f160e86/att
achment.png>

------------------------------

_______________________________________________
Leish-l mailing list
Leish-l at lineu.icb.usp.br
http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l


End of Leish-l Digest, Vol 101, Issue 2
***************************************

--
This email was sent by icb.usp.br


From jayusp at gmail.com  Mon Nov 28 20:21:07 2016
From: jayusp at gmail.com (Jeffrey Shaw)
Date: Mon, 28 Nov 2016 20:21:07 -0200
Subject: [Leish-l] [Possivel Spam] Fwd: Fw: PRO/AH/EDR> Leishmaniasis - USA:
	new guidelines, IDSA
In-Reply-To: <DBXPR05MB49450399F836A701F59440BCB8A0@DBXPR05MB494.eurprd05.prod.outlook.com>
References: <0100015895fb0ff0-0960b9b2-d42f-449f-ba4f-56afffe59c9d-000000@email.amazonses.com>
	<CAChMjg91bWY7mnt-N2o+CsufJVKvgL-6NFWENPDEjJFZW96Bhg@mail.gmail.com>
	<DBXPR05MB49452721F6AB99D987D5B90CB8A0@DBXPR05MB494.eurprd05.prod.outlook.com>
	<DBXPR05MB49450399F836A701F59440BCB8A0@DBXPR05MB494.eurprd05.prod.outlook.com>
Message-ID: <CAJ0ZN-ysEFeij93iN+Q1F8GWCx_ofNO5cWP_BTA_BUiEtsxBaw@mail.gmail.com>

------------------------------
*Subject:* Fwd: PRO/AH/EDR> Leishmaniasis - USA: new guidelines, IDSA
 ubject: PRO/AH/EDR> Leishmaniasis - USA: new guidelines, IDSA
To: promed-post at promedmail.org, promed-edr-post at promedmail.org,
promed-ahead-post at promedmail.org


LEISHMANIASIS - USA: NEW GUIDELINES, INFECTIOUS DISEASES SOCIETY OF
AMERICA
***************************************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Tue 15 Nov 2016
Source: Infectious Diseases Society of America (IDSA) press release
[edited]
<http://www.idsociety.org/Press_Release_11_15_2016/>


Driven by burgeoning ecotourism and military campaigns in Iraq and
Afghanistan, a parasitic infection called leishmaniasis is showing up
in more US patients, often stumping doctors. Rapid diagnostic tests
and innovative treatments are among the strategies to address
leishmaniasis highlighted in new guidelines released by the Infectious
Diseases Society of America (IDSA) and the American Society of
Tropical Medicine and Hygiene (ASTMH) and published in the journal
Clinical Infectious Diseases [see reference below].

The bite of the nearly invisible sand fly ?- 1/3 the size of a
mosquito -? transmits the leishmania parasite. The parasite is found
in more than 90 countries around the world ?- including Mexico and
those in Central and South America, Asia, Africa, the Middle East, and
southern Europe.

The infection rarely occurs in the United States, although a few cases
have been reported to have been acquired in Texas and Oklahoma. The
growth of travelers, soldiers, and immigrants with leishmaniasis being
seen by US doctors and the complicated diagnosis and management of the
disease drove the creation of these guidelines, the 1st in the United
States.

"Leishmaniasis is an increasingly common infection in ecotourists
traveling to Central and South America. Travelers visiting the jungle
in the Amazon basin have a high likelihood of being exposed," said
Naomi E Aronson, MD, lead author of the guidelines. "The cutaneous and
mucosal forms of the infection cause serious scarring and visceral
leishmaniasis can be deadly, so timely diagnosis and treatment managed
by an infectious diseases physician is vital. Because it's still
relatively uncommon in the United States, many doctors are unfamiliar
with leishmaniasis and don't suspect it when diagnosing patients.

The sore at the site of an infected sand fly bite often is painless
and symptoms of the infection may not show up for a month or longer,
further complicating the diagnosis. More than 20 types of leishmania
parasites cause human infection.

The 3 main clinical syndromes, often determined by the specific
parasite, are:
- cutaneous leishmaniasis (CL): CL causes skin sores, such as bumps or
lumps that may turn into ulcers with a central crater or scab over.
This is the commonest type of leishmaniasis, with an estimated 700 000
to 1.2 million cases worldwide every year, according to the Centers
for Disease Control and Prevention (CDC).
- mucosal leishmaniasis (ML): CL can metastasize, or spread, to mucous
membranes, especially the mouth and nose, resulting in ML. ML most
often occurs when the patient is infected by leishmania parasites from
Central or South America. Untreated, ML can cause serious scarring and
deformity.
- visceral leishmaniasis (VL): the most serious form, active VL is a
systemic infection that is almost always fatal if not treated.
Symptoms include weeks to months of high fevers, significant weight
loss, an enlarged spleen and low blood counts. CDC estimates there are
200 000 to 400 000 new cases of VL a year.

When doctors see infections with these symptoms, they should ask if
the patient has traveled outside of North America, Dr Aronson notes.

CL can be tested by polymerase chain reaction (PCR) or by doing a
culture to identify the type of leishmania and determine how
aggressively it should be treated. A blood test called rK39 provides a
rapid result if VL is suspected, which would be confirmed with PCR or
culture.

Oral miltefosine was approved by the Food and Drug Administration
(FDA) in 2014 for specific cases of cutaneous, mucosal, and visceral
leishmaniasis. "It may become a game-changer for treating
leishmaniasis as it is a pill that can be used for all 3 leishmaniasis
syndromes, depending on the parasite species responsible for the
infection," said Dr Aronson.

In addition, the ThermoMed(TM) [heat therapy] device can be used to
heat treat CL. FDA-approved liposomal amphotericin B is given
intravenously (IV) for VL. While more than 80 per cent effective,
these therapies don't always eradicate the parasite, and sometimes
additional treatment is necessary.

Despite the name, the fly that transmits the parasite also lives in
rotting vegetation in jungle areas. The sand fly most often bites
exposed skin at night, transmitting the parasite. While there are no
vaccines or preventive medications for leishmaniasis, people traveling
to areas where the parasite exists should use protective measures to
avoid infection. That includes wearing protective clothing (long
sleeves and pants), applying insect repellents containing DEET, and
using insecticide-impregnated bed nets.

[Reference
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of
leishmaniasis: clinical practice guidelines by the Infectious Diseases
Society of America (IDSA) and the American Society of Tropical
Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016; doi:
10.1093/cid/ciw670. First published online 14 Nov 2016; available at
<http://cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full>]

--
communicated by:
ProMED-mail
<promed at promedmail.org>

[ProMED-mail posts extensively on leishmaniasis worldwide (see
postings in 2016 listed below). It is also important to inform
physicians that immunocompromised patients, for instance those
receiving TNF-inhibitors or being HIV positive, do often not respond
to standard treatment.

A country specific recent review of leishmaniasis was published by J
Alvar and colleagues in 2012 (Alvar J, V?lez ID, Bern C, et al. WHO
Leishmaniasis Control Team: Leishmaniasis worldwide and global
estimates of its incidence. PLoS One. 2012; 7(5): e35671. doi:
10.1371/journal.pone.0035671;
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035671>).
- Mod.EP

A HealthMap/ProMED-mail map can be accessed at:
<http://healthmap.org/promed/p/106>.]

[See Also:
Leishmaniasis - Brazil (02): new sandfly vect susp, Psathyromyia
elizabethdorvalae http://promedmail.org/post/20161101.4600154
Leishmaniasis, visceral - Brazil: (MG) children
http://promedmail.org/post/20161029.4593491
Leishmaniasis, visceral - Nepal: (MO)
http://promedmail.org/post/20161002.4531103
Leishmaniasis, visceral - South Sudan: (UN)
http://promedmail.org/post/20160910.4479134
Leishmaniasis, cutaneous - Syria (03): (HL)
http://promedmail.org/post/20160821.4430681
Leishmaniasis, cutaneous - Pakistan (05): (TA)
http://promedmail.org/post/20160717.4350532
Leishmaniasis, cutaneous - Syria (02)
http://promedmail.org/post/20160630.4319680
Leishmaniasis, cutaneous - Syria: refugees
http://promedmail.org/post/20160529.4252805
Leishmaniasis, cutaneous - Palestinian Auth: (WE)
http://promedmail.org/post/20160528.4250881
Leishmaniasis, cutaneous - Pakistan (04): (NW) EpiCore responses
http://promedmail.org/post/20160521.4236192
Leishmaniasis, cutaneous - Pakistan (03): (NW)
http://promedmail.org/post/20160518.4230112
Leishmaniasis, cutaneous - Colombia: (NS) alert
http://promedmail.org/post/20160429.4192208
Leishmaniasis, cutaneous - Pakistan: (02): (NW)
http://promedmail.org/post/20160418.4167556
Leishmaniasis, cutaneous - Iraq: (DA) Yazidi refugees
http://promedmail.org/post/20160415.4161067
Leishmaniasis, cutaneous - Libya: (TR)
http://promedmail.org/post/20160414.4160311
Leishmaniasis - Colombia: (TO) RFI
http://promedmail.org/post/20160403.4136205
Leishmaniasis, canine - France
http://promedmail.org/post/20160220.4033101
Leishmaniasis, cutaneous - Pakistan: (TA)
http://promedmail.org/post/20160217.4027519
Leishmaniasis - Albania, Jordan, Pakistan: surveillance 2015
http://promedmail.org/post/20160210.4009452
Leishmaniasis - Uruguay: (SA) canine, alert
http://promedmail.org/post/20160122.3952222]
.................................................sb/ep/mj/sh
*##########################################################*
************************************************************
ProMED-mail makes every effort to  verify  the reports  that
are  posted,  but  the  accuracy  and  completeness  of  the
information,   and  of  any  statements  or  opinions  based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by  ProMED-mail.   ISID
and  its  associated  service  providers  shall not be  held
responsible for errors or omissions or  held liable for  any
damages incurred as a result of use or reliance upon  posted
or archived material.
************************************************************
Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>
************************************************************
Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed at promedmail.org (NOT to
an individual moderator).  If you do not give your full name
name and affiliation,  it may not be posted.  You may unsub-
scribe at  <http://ww4.isid.org/promedmail/subscribe.php>.
For  assistance  from   a   human   being, send mail to:
<postmaster at promedmail.org>.
############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20161128/18b600ce/attachment.htm>